Immunmediierte Epilepsien – moderne Behandlungsstrategien

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Dr. Judith Wagner

Klinik für Neurologie 1, Kepler Universitätsklinikum, Linz


Literatur:
  1. Vezzani A, French J, Bartfai T, Baram TZ, The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7(1):31–40. DOI: 10.1038/nrneurol.2010.178
  2. Wesselingh R, Butzkueven H, Buzzard K, Tarlinton D, O‘Brien TJ, Monif M, Seizures in autoimmune encephalitis: Kindling the fire. Epilepsia 2020; 61(6):1033–1044, DOI: 10.1111/epi.16515
  3. Shen CH, Fang GL, Yang F et al., Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABAB R encephalitis [published online ahead of print, 2020 Jul 25]. Ann Clin Transl Neurol 2020; 10.1002/acn3.51137, DOI: 10.1002/acn3.51137
  4. Moise AM, Karakis I, Herlopian A et al., Continuous EEG Findings in Autoimmune Encephalitis [published online ahead of print, 2019 Dec 2]. J Clin Neurophysiol 2019;10.1097/WNP.0000000000000654. DOI: 10.1097/WNP.0000000000000654
  5. Bauer J, Becker AJ, Elyaman W, et al. Innate and adaptive immunity in human epilepsies. Epilepsia 2017; 58 Suppl 3(Suppl Suppl 3):57-68, DOI: 10.1111/epi.13784
  6. Zuliani L, Nosadini M, Gastaldi M et al., Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci 2019; 40(10):2017–2030
  7. Dubey D, Britton J, McKeon A et al., Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. Ann Neurol. 2020; DOI: 87(2):313–323, DOI: 10.1002/ana.25655
  8. Titulaer MJ, McCracken L, Gabilondo I et al., Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12(2):157–165. DOI: 10.1016/S1474-4422(12)70310-1
  9. Cordani R, Micalizzi C, Giacomini T et al., Bortezomib-Responsive Refractory Anti-N-Methyl-d-Aspartate Receptor Encephalitis. Pediatr Neurol 2020; 103:61–64, DOI: 10.1016/j.pediatrneurol.2019.09.004
  10. Scheibe F, Prüss H, Mengel AM et al., Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 2017; 88(4):366–370 DOI:10.1212/WNL.0000000000003536
  11. Lee WJ, Lee ST, Moon J et al., Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurotherapeutics 2016; 13(4):824–832 DOI: 10.1007/s13311-016-0442-6
  12. de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH et al., Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 2019; 92(19):e2185-e2196, DOI: 10.1212/WNL.0000000000007475
  13. Feyissa AM, López Chiriboga AS, Britton JW, Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm 2017 ; 4(4):e353. Published 2017 May 10. DOI: 10.1212/NXI.0000000000000353
  14. Carreño M, Bien CG, Asadi-Pooya AA et al., Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017; 129:101–105, DOI: 10.1016/j.eplepsyres.2016.12.010
  15. Alsaadi T, Shakra M, Turkawi L, Hamid J, VNS terminating refractory nonconvulsive SE secondary to anti-NMDA encephalitis: A case report. Epilepsy Behav Case Rep 2015; 3:39–42 Published 2015 May 15. DOI: 10.1016/j.ebcr.2015.02.003
  16. Mäkelä KM, Hietaharju A, Brander A, Peltola J, Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-epileptic Drugs. Front Neurol 2018; 9:579, Published 2018 Jul 13. DOI: 10.3389/fneur.2018.00579

neuro Nachlese

Herausgeber: Österreichische Gesellschaft für Neurologie, Univ.-Prof. Dr. Thomas Berger, MSc, Präsident der ÖGN
Publikationsdatum: 2020-11-12